Article
Cell Biology
Sonia Brun, Eloine Bestion, Eric Raymond, Firas Bassissi, Zuzana Macek Jilkova, Soraya Mezouar, Madani Rachid, Marie Novello, Jennifer Tracz, Ahmed Hamai, Gilles Lalmanach, Lise Vanderlynden, Raphael Legouffe, Jonathan Stauber, Thomas Schubert, Maximilian G. Plach, Jerome Courcambeck, Cyrille Drouot, Guillaume Jacquemot, Cindy Serdjebi, Gael Roth, Jean-Pierre Baudoin, Christelle Ansaldi, Thomas Decaens, Philippe Halfon
Summary: The new autophagy inhibitor GNS561 shows high liver tropism and potent antitumor activity, particularly against hepatocellular carcinoma. Its mechanism of action involves lysosomal disruption and induction of cell death in tumor cells.
Article
Cell Biology
Chubin Luo, Haoyang Xin, Dan Yin, Tongyi Zhao, Zhiqiang Hu, Zhengjun Zhou, Rongqi Sun, Na Yao, Qiman Sun, Jia Fan, Xiaowu Huang, Jian Zhou, Shaolai Zhou
Summary: Sarcomatoid hepatocellular carcinoma (sHCC) is a rare liver malignancy with poorly understood tumor immune features. A study on 31 patients with resected sHCC revealed higher expressions of PD-L1 and B7-H3 in sarcomatoid components, along with higher densities of FOXP3(+) and LAG-3(+) cells and lower CD8(+) cell density compared to conventional HCC components. Higher PD-L1 expression in tumor cells correlated with higher densities of CD8(+), PD-1(+), and LAG-3(+) cells, and was associated with poor overall and disease-free survival in sHCC patients. These findings suggest potential therapeutic targets for immunotherapy in sHCC.
Article
Immunology
Yongbiao Huang, Shanshan Huang, Li Ma, Yali Wang, Xi Wang, Lingyan Xiao, Wan Qin, Long Li, Xianglin Yuan
Summary: This study revealed that H2AFY is upregulated in HCC tissues and cells, and high H2AFY expression is an independent prognostic factor for poor survival in HCC patients. Functional network analysis showed that H2AFY and its co-expressed genes regulate cell cycle, mitosis, spliceosome, and chromatin assembly through pathways involving various cancer-related kinases and E2F family. Moreover, significant correlations were observed between H2AFY expression and immune infiltration in HCC. Knockdown of H2AFY suppressed cell proliferation and migration, promoted cell cycle arrest, and induced apoptosis in HCC cells in vitro.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Cell Biology
Jun Hui Xu, Yong Jun Guan, Yi Chao Zhang, Zhen Dong Qiu, Yu Zhou, Chen Chen, Jia Yu, Wei Xing Wang
Summary: ADAM15 is highly expressed in hepatocellular carcinoma (HCC), linked to poor prognosis, and associated with tumor infiltrating lymphocytes. It also affects the expression of immune checkpoint genes. Knockdown of ADAM15 suppresses tumor cell proliferation, migration, and invasion, while its overexpression has opposite effects. These findings suggest ADAM15 as a potential biomarker for HCC diagnosis and treatment.
Article
Oncology
Shanshan Liu, Wei Zhao, Xuemei Li, La Zhang, Yu Gao, Qiling Peng, Chengyou Du, Ning Jiang
Summary: AGTRAP was found to be highly expressed in HCC tissues compared to normal liver tissues, associated with higher histological grade and poor overall survival in HCC patients. It showed potential as a diagnostic marker with high sensitivity and specificity in HCC, possibly involving the NF-kappa B and MAPK signaling pathways and correlating with immune cell infiltration and T-cell exhaustion.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Ting Liu, Zhi-zhao Li, Lei Sun, Kun Yang, Jia-min Chen, Xiao-yi Han, Li-ming Qi, Xin-gang Zhou, Peng Wang
Summary: CANT1 is highly expressed in hepatocellular carcinoma (HCC) and is associated with clinical features and poor prognosis. It is involved in regulating biological processes such as cell cycle and DNA replication and is independently associated with immune cell infiltration and prognosis in HCC.
Article
Gastroenterology & Hepatology
Jinlan Huang, Siyi Xu, Zhou Yu, Yansong Zheng, Bin Yang, Qishui Ou
Summary: ATP13A2 is upregulated in hepatocellular carcinoma and is associated with prognosis, potentially regulating cell cycle, metastasis, and immune infiltrates.
JOURNAL OF GASTROINTESTINAL SURGERY
(2023)
Article
Biochemistry & Molecular Biology
Haiyuan Li, Lei Gao, Xiaojuan Kang, Xueyan Wang, Yang Yu, Yaqing Zhang, Hao Chen
Summary: This study explored the expression and function of 40S ribosomal protein S24 (RPS24) in hepatocellular carcinoma (HCC). Results showed that RPS24 was elevated in HCC samples and related to poor prognosis. Furthermore, RPS24 overexpression or promoter methylation correlated with unfavorable prognosis in HCC patients. High expression of RPS24 was associated with DNA replication, cell cycle, immune infiltration, and immunotherapy response. Experimental validation demonstrated that silencing of RPS24 suppressed HCC cell growth and tumor proliferation. Therefore, RPS24 may serve as a potential adverse biomarker for HCC prognosis, acting through cell proliferation facilitation and the formation of an immunosuppressive microenvironment, and targeting RPS24 could be a promising therapeutic option for HCC management.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Genetics & Heredity
Tianhao Cong, Yingen Luo, Yu Liu, Chao Yang, Hongcai Yang, Yujie Li, Jingui Li, Xiao Li
Summary: The relationship between cuproptosis, a novel cell death pathway, and anti-tumor immunity in hepatocellular carcinoma (HCC) is explored in this study. By identifying cuproptosis-related immune checkpoint genes (ICGs), a prognostic risk signature is constructed and shown to independently predict overall survival. The study also reveals the robustness of the signature-immune cell infiltration relationship and the potential influence of various pathways on HCC prognosis and immune infiltration.
FRONTIERS IN GENETICS
(2022)
Article
Cell Biology
Dafeng Xu, Yu Wang, Jincai Wu, Yuliang Zhang, Zhehao Liu, Yonghai Chen, Jinfang Zheng
Summary: This study identified 64 common DEIGs enriched in tumor immunologic related signaling pathways and constructed a 5-gene signature risk model to predict the prognosis of HCC patients. Different immune expression characteristics lead to different prognostic outcomes. The model showed better performance compared to existing ones and had strong robustness across different cohorts.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Wei Tian, Chenyu Li, Jiaqi Ren, Pengfei Li, Jingyuan Zhao, Shuai Li, Deshi Dong
Summary: This study identified lysosome-related genes involved in hepatocellular carcinoma (HCC) progression and validated the prognostic value of the palmitoyl protein thioesterase 1 (PPT1) gene. PPT1 was found to promote HCC cell proliferation and affect the metabolism, localization, and function of macromolecular proteins. These findings suggest that PPT1 could be a promising therapeutic target for HCC treatment.
BIOSCIENCE REPORTS
(2023)
Article
Cell Biology
Yongqi Ding, Yiyang Gong, Hong Zeng, Xuanrui Zhou, Zichuan Yu, Jingying Pan, Minqin Zhou, Shiwen Liu, Wei Lai
Summary: ARHGAP39 is highly expressed in hepatocellular carcinoma and associated with clinicopathological features. It worsens the prognosis by increasing immune infiltration through chemokines and is also related to cell cycle, m6A modification, and drug resistance.
Article
Biochemistry & Molecular Biology
Shuqiao Zhang, Xinyu Li, Xiang Zhang, Shijun Zhang, Chunzhi Tang, Weihong Kuang
Summary: A novel pyroptosis-related genes signature was identified to predict the prognosis of HCC patients, showing good performance in survival analysis and association with immune response mechanisms.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2022)
Article
Immunology
Lin Ding, Qian Yu, Shuo Yang, Wen-Jing Yang, Te Liu, Jing-Rong Xian, Tong-Tong Tian, Tong Li, Wei Chen, Bei-Li Wang, Bai-Shen Pan, Jian Zhou, Jia Fan, Xin-Rong Yang, Wei Guo
Summary: This study suggests that HHLA2 is an independent prognostic biomarker for HCC patients, and it can activate the cell cycle and foster an immunosuppressive tumor microenvironment by enriching exhausted CD8+ T cells. Additionally, low expression of HHLA2 may be associated with promoter hypermethylation.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Ruijia Liu, Xu Cao, Yijun Liang, Xiaobin Li, Qian Jin, Ying Li, Hongbo Du, Xiaobin Zao, Yong'an Ye
Summary: This study found that ST6GAL1 is downregulated in hepatocellular carcinoma (HCC) and its downregulation is associated with a poor prognosis. ST6GAL1 may exert an anti-inflammatory function in the liver by regulating the infiltration of immune cells.
JOURNAL OF INFLAMMATION RESEARCH
(2022)
Article
Medical Laboratory Technology
Jianjun Xu, Yun Xia, Suzhen Li, Xiang Cheng, Shaobo Hu, Yang Gao, Xing Zhou, Guoliang Wang, Qichang Zheng
ANNALS OF CLINICAL BIOCHEMISTRY
(2019)
Article
Oncology
Zekun Lui, Kai Yu, Jian Zheng, Huan Lin, Qi Zhao, Xiaolong Zhan, Weiyi Feng, Liyu Wang, Jianjun Xu, Dawei Xie, Zhi-Xiang Zuo, Ze-Xian Liu, Qichang Zheng
Article
Medicine, General & Internal
Jianjun Xu, Shaobo Hu, Suzhen Li, Weimin Wang, Yuzhe Wu, Zhe Su, Xing Zhou, Yang Gao, Xiang Cheng, Qichang Zheng
Summary: The higher the SII value in HCC patients, the more likely they are to develop postoperative acute kidney injury, with SII >= 547.84 x 109/L being an independent predictor of pAKI.
Article
Medical Laboratory Technology
Jianjun Xu, Yang Gao, Shaobo Hu, Suzhen Li, Weimin Wang, Yuzhe Wu, Zhe Su, Xing Zhou, Xiang Cheng, Qichang Zheng
Summary: This study focused on predicting disease progression in COVID-19 patients in the early stages, finding that high concentrations of NLR, LDH, and IL-10 were independent risk factors. The risk model combining these factors improved the accuracy of predicting disease progression in early-stage COVID-19 patients.
ANNALS OF CLINICAL BIOCHEMISTRY
(2021)
Article
Biotechnology & Applied Microbiology
Jianjun Xu, Qichang Zheng, Xiang Cheng, Shaobo Hu, Chen Zhang, Xing Zhou, Ping Sun, Weimin Wang, Zhe Su, Tianhao Zou, Zifang Song, Yun Xia, Xiaoqing Yi, Yang Gao
Summary: A light-triggered nanoplatform co-loaded with a photosensitizer and paclitaxel was developed for synergistic chemo-photodynamic therapy in hepatocellular carcinoma. The nanoplatform specifically accumulated at the tumor site through active targeting and facilitated image-guided PDT for tumor ablation. This combined therapy approach showed enhanced anti-tumor effects and potential for inhibiting tumor relapse and metastasis.
JOURNAL OF NANOBIOTECHNOLOGY
(2021)
Article
Pharmacology & Pharmacy
Shaoshao Zhang, Leilei Fan, Yongjun Wang, Jianjun Xu, Qiang Shen, Jianhua Xie, Zhipeng Zeng, Tingwen Zhou
Summary: This study found that dihydromyricetin (DHM) can reduce the expression of interleukin-6 (IL-6) by inhibiting the phosphorylation of c-KIT protein, thus improving the osteogenic differentiation of valvular interstitial cells (VICs) and reducing the progression of calcific aortic valve disease (CAVD).
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Materials Science, Multidisciplinary
Yang Gao, Zhe Su, Cui Wang, Jianjun Xu, Shaobo Hu, Chen Zhang, Ping Sun, Xing Zhou, Weimin Wang, Tianhao Zou, Bing Yang, Xiang Cheng, Xiaoqing Yi, Qichang Zheng
Summary: Immune checkpoint blockade therapy is a promising approach for hepatocellular carcinoma treatment, but many patients do not respond due to low tumor antigen exposure and the immunosuppressive tumor microenvironment. Combination chemo-photodynamic therapy can enhance the effectiveness of immune checkpoint blockade therapy in eliminating tumors and boosting anti-tumor immune responses.
MATERIALS & DESIGN
(2023)
Article
Oncology
Jianjun Xu, Shaobo Hu, Suzhen Li, Weimin Wang, Xing Zhou, Yuzhe Wu, Zhe Su, Xiang Cheng, Yang Gao, Qichang Zheng
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2020)
Review
Oncology
Yuzhe Wu, Weimin Wang, Bin Shu, Min Li, Jianjun Xu, Qichang Zheng
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
(2020)
Review
Oncology
Jianjun Xu, Shaobo Hu, Suzhen Li, Yang Gao, Weimin Wang, Xing Zhou, Xiang Cheng, Qichang Zheng
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
(2019)